Cocrystal Pharma, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
COCP$1.03-6.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands)
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance as of December 31, 2022 | 8,143 | $8 | $337,489 | $(297,930) | $39,597 |
| Stock-based compensation | - | - | 801 | - | 801 |
| Sale of common stock to related entities, net of transaction costs | 2,031 | 2 | 3,998 | - | 4,000 |
| Net loss | - | - | - | (17,984) | (17,984) |
| Balance as of December 31, 2023 | 10,174 | $10 | $342,288 | $(315,914) | $26,384 |
| Stock-based compensation | - | - | 643 | - | 643 |
| Net loss | - | - | - | (17,504) | (17,504) |
| Balance as of December 31, 2024 | 10,174 | $10 | $342,931 | $(333,418) | $9,523 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.